These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2349079)

  • 1. Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease.
    Bosly A; Brice P; Humblet Y; Doyen C; Faille A; Chatelain B; Franks C; Gisselbrecht C; Symann M
    Nouv Rev Fr Hematol (1978); 1990; 32(1):13-6. PubMed ID: 2349079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune reconstitution after bone-marrow transplantation.
    Symann M; Bosly A; Gisselbrecht C; Brice P; Franks C
    Cancer Treat Rev; 1989 Jun; 16 Suppl A():15-9. PubMed ID: 2670211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
    Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
    Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
    Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
    Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients.
    Blaise D; Viens P; Olive D; Stoppa AM; Gabert J; Pourreau CN; Attal M; Gaspard MH; Mannoni P; Jasmin C
    Eur Cytokine Netw; 1991; 2(2):121-9. PubMed ID: 1813015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma.
    Valteau-Couanet D; Rubie H; Meresse V; Farace F; Brandely M; Hartmann O
    Bone Marrow Transplant; 1995 Oct; 16(4):515-20. PubMed ID: 8528166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution.
    Guillaume T; Sekhavat M; Rubinstein DB; Hamdan O; Leblanc P; Symann ML
    Cancer Res; 1994 Jul; 54(14):3800-7. PubMed ID: 7913409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Reconstitution of peripheral blood lymphocytes in patients treated with bone marrow transplantation: comparison between allogeneic and autologous transplantation].
    Parra C; Roldán E; Rodríguez C; Pérez de Oteyza J; Oteho E; López J; Maldonado MS; García Laraña J; Muñoz A; Odriozola J; Brieva JA
    Med Clin (Barc); 1999 Jun; 113(1):1-5. PubMed ID: 10422068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.
    Vey N; Viens P; Fossat C; Olive D; Sainty D; Baume D; Stoppa AM; Bouabdallah R; Brandely M; Gastaut JA; Maraninchi D; Blaise D
    Eur Cytokine Netw; 1997 Dec; 8(4):389-94. PubMed ID: 9459619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of immune reconstitution by interleukin-7 after syngeneic bone marrow transplantation in mice.
    Abdul-Hai A; Or R; Slavin S; Friedman G; Weiss L; Matsa D; Ben-Yehuda A
    Exp Hematol; 1996 Oct; 24(12):1416-22. PubMed ID: 8913288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
    Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
    Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow.
    Talmadge JE; Reed E; Ino K; Kessinger A; Kuszynski C; Heimann D; Varney M; Jackson J; Vose JM; Bierman PJ
    Bone Marrow Transplant; 1997 Jan; 19(2):161-72. PubMed ID: 9116614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coactivation with anti-CD28 monoclonal antibody enhances anti-CD3 monoclonal antibody-induced proliferation and IL-2 synthesis in T cells from autologous bone marrow transplant recipients.
    Lum LG; Joshi ID; Galoforo SC; Abella E; Karanes C; Ratanatharathorn V; Schultz KR; Uberti JP; Sensenbrenner LL; Ledbetter JA
    Bone Marrow Transplant; 1993 Dec; 12(6):565-71. PubMed ID: 8136739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
    Blaise D; Attal M; Reiffers J; Michallet M; Bellanger C; Pico JL; Stoppa AM; Payen C; Marit G; Bouabdallah R; Sotto JJ; Rossi JF; Brandely M; Hercend T; Maraninchi D
    Eur Cytokine Netw; 2000 Mar; 11(1):91-8. PubMed ID: 10705305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.